Northcoast Research expects Dentsply (NASDAQ:XRAY) to unveil a significantly improved competing product to Align's (NASDAQ:ALGN) Invisalign at the American Academy of Orthodontics conference next month.
Given Align's fancy valuation and a new competitive product on the horizon, it would be appropriate for investors to use caution in the short-term, says Northcoast.
Align, so far, is shrugging off the news, up 1.6% on the session. XRAY is up marginally.
Subscribe for full text news in your inbox